Acetylated Natural Nucleotides in Treating Hand-foot Syndrome

Hand-foot Syndrome Clinical Trial

Official title:

A Clinical Trial to Evaluate the Efficacy and Safety of Acetylated Natural Nucleotides in Treating Hand-foot Syndrome (HFS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04592731
• Other study ID #: SHEH001
• Status: Completed
• Phase: N/A
• Start date: November 3, 2020
• Est. completion date: June 1, 2022

Study information

• Verified date: February 2023
• Source: Shanghai East Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The clinical trial is planned to investigate the efficacy and safety of acetylated natural nucleotides in treating anti-cancer medications induced hand-foot syndrome (HFS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: June 1, 2022
• Est. primary completion date: April 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older.
• Pathologically con?rmed cancer receiving capecitabine-based anti-cancer therapy (capecitabine with or without other anti-cancer drugs).
• With HFS determined by "CTCAE v5.0 - PPE" as grade 2 or above.
• Able to use topical medications and complete questionnaires reliably with or without assistance.
• ECOG performance score < 2.

Exclusion Criteria:

• Has HFS due to other medications and does not recover within 4 weeks prior to baseline.
• Other skin disorders that will affect efficacy evaluation on the hands and feet, including but not limited to: tinea of feet and hands, hand/foot eczema, palmoplantar pustulosis, palmoplantar keratosis, acrodermatitis continua etc.
• Uncontrolled intercurrent illness as determined by the investigator including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, recent myocardial infarction, uncontrolled hypotension or hypertension, cardiac arrhythmia, or psychiatric illness and social situations that would limit compliance with study requirements.
• Significantly abnormal lab test:
• Inadequate hematologic function as indicated by:
• Absolute neutrophil counts (ANC) < 1,500 /mm^3
• Hemoglobin (Hgb) < 8.5 g/dL
• Platelet count < 75,000 /mm^3
• PT or PTT > 1.5 x ULN (if patients on anticoagulants: PT INR > 3.5 x ULN)
• Inadequate renal and liver function as indicated by:
• Albumin < 2.8 g/dL
• Total bilirubin > 1.5 x ULN (or > 2.5 x ULN for patients with Gilbert's syndrome)
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase > 2 x ULN
• Creatinine > 2 x ULN
• Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.

Related Conditions & MeSH terms

• Hand-foot Syndrome
• Syndrome

Intervention

Drug:
• Gel containing Acetylated Natural Nucleotides
The study drug is a gel containing acetylated natural nucleotides.
• Vehicle Gel
The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.

Locations

Country	Name	City	State
China	Shanghai East Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Nan xu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients who achieve "NCI CTCAE v5.0 - Palmar-Plantar Erythrodysesthesia (PPE)" grade 0 or 1	The proportion of patients who achieve "NCI CTCAE v5.0 - PPE" grade 0 or 1 at week 6 from grade 2 or above at baseline	6 weeks
Secondary	Safety of study drug	Safety of study drug as determined by number of participants with abnormal laboratory values and/or Adverse Events that are related to treatment	6 weeks
Secondary	Proportion of patients who achieve at least one grade improvement in HFS severity	The proportion of patients who achieve at least one grade improvement in HFS severity according to "NCI CTCAE v5.0 - PPE" by week 6	6 weeks
Secondary	Change from baseline in patient reported pain using Visual Analog Scale (VAS)	Change from baseline in patient reported pain using VAS at week 6. VAS is a scale used to determine the pain intensity experienced by individuals, which consists of a line 10 cm in length, with the left side signifying no pain and the right side signifying the worst pain ever.	6 weeks
Secondary	Change from baseline in Hand-Foot Skin Reaction and Quality of Life (HF-QoL) Questionnaire total score	Change from baseline in HF-QoL Questionnaire total score at week 6. HF-QoL questionnaire is comprised of a 20-item symptom domain and an 18-item daily activity domain. Each item is rated on a 5-point scale from 0 (not at all) to 4 (always or extremely) during the previous week. The HF-QoL symptom and daily activity total scores are transformed to a scale of 0 to 100, based on the sum of each unit-weighted item score divided by the maximum score. Higher scores on the HF-QoL indicate worse quality of life or greater symptom burden.	6 weeks
Secondary	The proportion of patients whose anti-cancer medications are impacted due to HFS	The proportion of patients who need temporary interruption or permanent discontinuation and/or dose reduction of anti-cancer medications due to HFS	6 weeks